ArticlePloS one2025
Prevalence and correlates of microalbuminuria in high-risk persons with hypertension, diabetes, or HIV at a tertiary hospital in Zambia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sex-specific correlates of microalbuminuria in high-risk adults: a cross-sectional study.BMC research notes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroalbuminuria is a critical marker for early kidney damage and a predictor for proteinuria, a defining feature of renal disease. Its detection in high-risk individuals is vital for reducing the risk of adverse renal outcomes, particularly among persons living with diabetes, hypertension, and HIV. The evaluation of microalbuminuria in high-risk individuals allows for the early detection of renal impairment and the assessment of cardiovascular risk profiles. Additionally, it informs targeted therapeutic interventions and provides critical prognostic information, thereby enhancing overall clinical outcomes. The goal of the study was to determine the prevalence and correlates of microalbuminuria in high risk patients.
methodsA cross-sectional study was conducted at Livingstone University Teaching Hospital (LUTH) from September 2023 to July 2024. We employed homogeneous purposive sampling to recruit 306 high-risk adults (≥18 years) with diabetes, hypertension, and/or HIV. Purposive sampling was employed to recruit patients attending routine medical clinic at LUTH. Sample size was calculated using the formula for a single proportion (expected prevalence: 30%, margin of error: 5%, 95% CI), yielding 323; we recruited 306 due to logistical constraints. Data were collected directly from participants as well as using hospital records and laboratory analysis of blood/urine samples. Descriptive and inferential statistics were analyzed using SPSS v22.
resultsA total of 306 high-risk individuals were screened, with a median age of 46 years (IQR: 31-58). Of these, 61.8% (n = 189) were females and 38.2% (n = 117) were males. The prevalence of microalbuminuria was 28.8% (95%CI 23.7-33.8), while its prevalence among individuals with diabetes, hypertension, and HIV was 45.4%, 33.3%, and 39.1%, respectively. Microalbuminuria was significantly associated with diabetes (p = 0.033), individuals living with HIV (p = 0.035), and high-sensitivity C-reactive protein (Hs-CRP) (p = 0.007) in univariate analysis. On multivariable analysis, microalbuminuria was associated with diabetes (AOR 2.90; 95% CI 1.02-8.19 p = 0.044), Living with HIV (AOR 1.96; 95%CI 1.02-3.78; p = 0.042) and Hs-CRP (AOR 1.16; 95%CI 1.02-1.30 p = 0.015).
conclusionThe findings underscore the importance of routine screening for microalbuminuria in high-risk populations. Early detection and intervention could prevent the progression of microalbuminuria to overt renal disease, particularly in individuals with diabetes, HIV, and systemic inflammation. Integrating microalbuminuria screening into chronic disease management programs is essential to mitigate renal complications in these vulnerable groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.